Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer

Basit Öğe Kaydı
dc.authoridYILMAZ, MUKADDES/0000-0002-7927-8480
dc.authoridUCAR, MAHMUT/0000-0002-3311-6152
dc.contributor.authorYilmaz, Mukaddes
dc.contributor.authorErdis, Eda
dc.contributor.authorUcar, Mahmut
dc.contributor.authorDemir, Necla
dc.contributor.authorAlandag, Celal
dc.contributor.authorYucel, Birsen
dc.date.accessioned2024-10-26T18:09:00Z
dc.date.available2024-10-26T18:09:00Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground In the current study, the effect of hormone receptor (HR) status on clinical and survival in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer was investigated. Methods Two hundred ninety-one patients with HER2- positive were examined in two categories as HR-positive and HR-negative. Results Of these, 197 (68%) were HR-positive and 94 (32%) were HR-negative with a mean follow-up period of 68 +/- 2.7 months. The groups were found to be similar in terms of age, menopausal status, comorbidity, pathologic type, stage, T stage, N stage, lymphovascular invasion, presence and percentage of intraductal component, multicentricity/focality and extracapsular invasion. Family history (P = 0.038), stage 2 tumor rate (P < 0.001), and perineural invasion (P = 0.005) were significantly higher in the HR-positive group. In the HR-negative group, mean Ki-67 value (P = 0.014), stage 3 tumor rate (P < 0.001), tumor necrosis (P = 0.004) and strong (3+) HER2 staining on immunohistochemical staining (P = 0.003) were higher. The incidence of relapse and metastasis, and the localization of metastasis were similar in both patient groups. The rate of locoregional relapse during the first 2 years was higher in the HR-negative patients than in the HR-positive patients (P = 0.023). Overall survival (OS) and disease-free survival (DFS) did not differ between the groups in univariate analysis. However, HR status was determined as an independent prognostic factor (HR: 2.11, 95% CI: 1.17-3.79; P = 0.012) for OS was not found to be significant for DFS in multivariate analysis. Conclusion Both clinicopathologic features and OS outcomes of HR-negative patients were worse than those of HR-positive patients.
dc.identifier.doi10.1093/jjco/hyae010
dc.identifier.endpage529
dc.identifier.issn0368-2811
dc.identifier.issn1465-3621
dc.identifier.issue5
dc.identifier.pmid38336481
dc.identifier.scopus2-s2.0-85192681853
dc.identifier.scopusqualityQ2
dc.identifier.startpage521
dc.identifier.urihttps://doi.org/10.1093/jjco/hyae010
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29889
dc.identifier.volume54
dc.identifier.wosWOS:001160950900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofJapanese Journal of Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectbreast cancer
dc.subjectHER2
dc.subjecthormone receptor
dc.subjectsurvival
dc.subjectclinical features
dc.titleEffects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu